Affymax(OTC) AFFY

Market Cap$37.50K

Since IPO (2006)-100%

5 Year-98%

1 Year+25%

1 Month-23%

$0.00

+0%

+0.00Today

Affymax last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-24

Affymax stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-17
1 month	-23.08%	USD 0.00	2026-06-24
3 month	-9.09%	USD 0.00	2026-04-22
Year to date	+25%	USD 0.00	2025-12-31
1 year	+25%	USD 0.00	2025-07-23
3 year	-76.74%	USD 0.00	2023-07-25
5 year	-97.5%	USD 0.04	2021-07-23
Since inception	-100%	USD 20.33	2006-12-15

Affymax Financials at a Glance

Market Cap

$37.50K

Revenue (TTM)

$42.33K

Net Income (TTM)

$2.69M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-12.09 (Low)

Dividend

$0.00

Beta (Volatility)

-12.09 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2025

Dividend

$0.00

Beta (Volatility)

-12.09 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2025

AFFY News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Affymax

Affymax, Inc. is a biotechnology company focused on developing pharmaceutical agents aimed at improving therapies for severe health issues. Established in 2001 and based in New York City, the company currently has limited operational activities.

Products and Services

Development of pharmaceutical agents for critical health conditions
Focus on therapies that address severe and often fatal diseases
Research initiatives aimed at innovative healthcare solutions

Growth Outlook

Potential for future product development in the biotechnology sector
Strategic partnerships could enhance research capabilities
Market demand for innovative therapies remains strong

Financial Highlights

Recent quarterly revenue of $42,000, showing potential for growth
Trailing twelve months (TTM) gross profit margin of 99.12%
Cash and cash equivalents of $3,399,000 as of June 30, 2014

Affymax, Inc. operates in a challenging environment, yet it holds potential for future growth through its focus on critical health issues. The company's recent revenue indicates a step towards operational recovery, while its high gross profit margin suggests effective cost management. With a solid cash position, Affymax is positioned to explore new opportunities in the biotechnology sector, which is characterized by increasing demand for innovative therapies. The strategic direction and potential partnerships may further enhance its capabilities, making it an intriguing option for investors interested in the biotechnology field.

AI Generated • Jul 23, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

New York City, NY 10020, US

AFFY Financials

Key Financial Metrics (TTM)

Gross Margin

99.12%

Operating Margin

-1099.05%

Net Income Margin

-1053.62%

Return on Equity

-420.95%

Return on Capital

N/A

Return on Assets

-193.79%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$37.50K

Shares Outstanding

37.49M

Volume

Avg. Volume

928.452

Financials (TTM)

Gross Profit

$42.11K

Operating Income

-$5.49M

EBITDA

-$5.19M

Operating Cash Flow

-$8.37M

Capital Expenditure

$0.00

Free Cash Flow

-$8.37M

Cash & ST Invst.

$3.40M

Total Debt

$0.00

Affymax Performance Analysis

Affymax sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2013-09-30	-99.9%
Q4	2013-12-31	-100.0%
Q1	2014-03-31	N/A
Q2	2014-06-30	N/A

Affymax sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2013-09-30	-111.0%
Q4	2013-12-31	-84866.7%
Q1	2014-03-31	99.9%
Q2	2014-06-30	612.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2014YOY CHG

Revenue

$42.00K

-92.0%

Gross Profit

$42.00K

-92.0%

Gross Margin

100.00%

N/A

Market Cap

$37.50K

N/A

Market Cap/Employee

$18.75K

N/A

Employees

N/A

Net Income

$7.21M

-53.1%

EBITDA

-$1.02M

-107.1%

Quarterly Fundamentals

Name

Q2 2014YOY CHG

Total Cash

$3.40M

-67.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.94%

N/A

Return on Invested Capital

10.54%

N/A

Free Cash Flow

-$1.46M

+96.0%

Operating Cash Flow

-$1.46M

+96.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AMBSAmarantus BioScience Holdings, Inc.

AMBSAmarantus BioScience Holdings, Inc.$0.00+0.00%

ENDVEndonovo Therapeutics, Inc.

ENDVEndonovo Therapeutics, Inc.$0.00+0.00%

ITMCItoco Inc.

ITMCItoco Inc.$0.00+0.00%

VFRMVeritas Farms, Inc.

VFRMVeritas Farms, Inc.$0.00+0.00%

WIBFFWest Island Brands Inc.

WIBFFWest Island Brands Inc.$0.00+0.00%

GNLKQGeneLink, Inc.

GNLKQGeneLink, Inc.$0.00+0.00%

CNBXCNBX Pharmaceuticals Inc.

CNBXCNBX Pharmaceuticals Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$8.41-0.06%

TAT&T

TAT&T$23.94-0.03%

SMRNuScale Power

SMRNuScale Power$7.59-0.08%

ORCLOracle

ORCLOracle$117.74-0.02%

CMGChipotle Mexican Grill

CMGChipotle Mexican Grill$34.24+0.02%

CVNACarvana

CVNACarvana$66.32+0.00%

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF$100.68+0.00%

Questions About AFFY

What is the current price of Affymax?

Affymax is trading at $0.00 per share.

What is the 52-week range for Affymax?

Over the past 52 weeks, Affymax has traded between $0.00 and $0.00.

How much debt does Affymax have?

Affymax total debt is unavailable.

How much cash does Affymax have on hand?

Affymax does not have cash on hand data available.

What is Affymax’s dividend yield?

Affymax does not currently have a dividend yield.

Affymax(OTC) AFFY

Affymax Financials at a Glance

AFFY News

The Nasdaq's 5 Most Hated Stocks

3 Reasons Investors Are Scared of Biotech Stocks

5 of Last Week's Biggest Losers

3 Ways You Can Be a Successful Biotech Investor

Pharmaceuticals: Just What the Dow Ordered

Down 60%: Affymax Cuts to the Bone

3 Can't-Miss Health-Care Events This Week

Steer Clear of Affymax's Mysterious Pop

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Affymax

AFFY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Affymax Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AFFY

What is the current price of Affymax?

What is the 52-week range for Affymax?

How much debt does Affymax have?

How much cash does Affymax have on hand?

What is Affymax’s dividend yield?

Premium Investing Services